News

Video

Fatigue or Autoimmune Disease? Physician Talks Immunotherapy Side Effects

Author(s):

Yvonne Saenger, MD

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team.

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team at the Society for Immunotherapy of Cancer (SITC) 101 session.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Image of Staci.
Image of woman, with text.
Image of woman with text.
Related Content
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects: © stock.adobe.com.
August 1st 2025

New Treatment Combo Improves Advanced Melanoma Outcomes

Spencer Feldman
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects.
cancer horizons podcast logo: a white microphone on a blue background
August 1st 2025

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of man with text..
August 1st 2025

Key Skin Cancer Treatment Updates From 2025 and What is Still to Come

Ryan Scott
Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for patients with high-risk skin cancer.
CURE Cancer Horizons logo
August 1st 2025

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
A A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma: © stock.adobe.com.
August 1st 2025

Real-World Data Supports Amtagvi’s Benefit in Advanced Melanoma

Spencer Feldman
A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.
TIL therapy is on the rise in melanoma, with potential for other tumor types.
August 1st 2025

Empowering the Immune System

Darlene Dobkowski, MA
TIL therapy is on the rise in melanoma, with potential for other tumor types.